Literature DB >> 29472352

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.

Jorge J Castillo1,2, Joshua N Gustine3, Kirsten Meid3, Toni Dubeau3, Patricia Severns3, Steven P Treon3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472352      PMCID： PMC6029546          DOI： 10.3324/haematol.2017.186908

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Roger G Owen; Steven P Treon; Ayad Al-Katib; Rafael Fonseca; Philip R Greipp; Mary L McMaster; Enrica Morra; Gerassimos A Pangalis; Jesus F San Miguel; Andrew R Branagan; Meletios A Dimopoulos
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 2.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Robert A Kyle; Steven P Treon; Raymond Alexanian; Bart Barlogie; Magnus Björkholm; Madhav Dhodapkar; T Andrew Lister; Giampaolo Merlini; Pierre Morel; Marvin Stone; Andrew R Branagan; Véronique Leblond
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

3.  Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Authors:  Li Ren; Amanda Campbell; Huiqing Fang; Shalini Gautam; Saranya Elavazhagan; Kavin Fatehchand; Payal Mehta; Andrew Stiff; Brenda F Reader; Xiaokui Mo; John C Byrd; William E Carson; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

4.  CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

Authors:  Josephine M Vos; Nickolas Tsakmaklis; Christopher J Patterson; Kirsten Meid; Jorge J Castillo; Philip Brodsky; Tomas Ganz; Steven T Pals; Marie José Kersten; Lian Xu; Guang Yang; Steven P Treon; Zachary R Hunter
Journal:  Haematologica       Date:  2017-08-10       Impact factor: 9.941

Review 5.  Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.

Authors:  Jorge J Castillo; M Lia Palomba; Ranjana Advani; Steven P Treon
Journal:  Ther Adv Hematol       Date:  2016-06-13

Review 6.  How I manage ibrutinib-refractory chronic lymphocytic leukemia.

Authors:  Jennifer A Woyach
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

7.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

8.  Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Authors:  Meletios A Dimopoulos; Judith Trotman; Alessandra Tedeschi; Jeffrey V Matous; David Macdonald; Constantine Tam; Olivier Tournilhac; Shuo Ma; Albert Oriol; Leonard T Heffner; Chaim Shustik; Ramón García-Sanz; Robert F Cornell; Carlos Fernández de Larrea; Jorge J Castillo; Miquel Granell; Marie-Christine Kyrtsonis; Veronique Leblond; Argiris Symeonidis; Efstathios Kastritis; Priyanka Singh; Jianling Li; Thorsten Graef; Elizabeth Bilotti; Steven Treon; Christian Buske
Journal:  Lancet Oncol       Date:  2016-12-10       Impact factor: 41.316

9.  Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.

Authors:  Carsten U Niemann; Sarah E M Herman; Irina Maric; Julio Gomez-Rodriguez; Angelique Biancotto; Betty Y Chang; Sabrina Martyr; Maryalice Stetler-Stevenson; Constance M Yuan; Katherine R Calvo; Raul C Braylan; Janet Valdez; Yuh Shan Lee; Deanna H Wong; Jade Jones; Clare Sun; Gerald E Marti; Mohammed Z H Farooqui; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-12-09       Impact factor: 12.531

10.  The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.

Authors:  Lingyan Ping; Ning Ding; Yunfei Shi; Lixia Feng; Jiao Li; Yalu Liu; Yufu Lin; Cunzhen Shi; Xing Wang; Zhengying Pan; Yuqin Song; Jun Zhu
Journal:  Oncotarget       Date:  2017-06-13
  10 in total
  13 in total

1.  Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.

Authors:  Paul J Hampel; Timothy G Call; Kari G Rabe; Wei Ding; Eli Muchtar; Saad S Kenderian; Yucai Wang; Jose F Leis; Thomas E Witzig; Amber B Koehler; Amie L Fonder; Susan M Schwager; Daniel L Van Dyke; Esteban Braggio; Susan L Slager; Neil E Kay; Sameer A Parikh
Journal:  Oncologist       Date:  2020-09-20

2.  Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Authors:  Paul J Hampel; Wei Ding; Timothy G Call; Kari G Rabe; Saad S Kenderian; Thomas E Witzig; Eli Muchtar; Jose F Leis; Asher A Chanan-Khan; Amber B Koehler; Amie L Fonder; Susan M Schwager; Susan L Slager; Tait D Shanafelt; Neil E Kay; Sameer A Parikh
Journal:  Leuk Lymphoma       Date:  2019-04-24

Review 3.  Management of Waldenström macroglobulinemia in 2020.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Treatment options for relapsed Waldenström's Macroglobulinemia.

Authors:  Alexander Grunenberg; Christian Buske
Journal:  Hemasphere       Date:  2019-06-30

5.  Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.

Authors:  Santiago Thibaud; Douglas Tremblay; Sheena Bhalla; Brittney Zimmerman; Keith Sigel; Janice Gabrilove
Journal:  Br J Haematol       Date:  2020-06-04       Impact factor: 6.998

6.  Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.

Authors:  Aristea-Maria Papanota; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Meletios A Dimopoulos; Maria Gavriatopoulou
Journal:  J Blood Med       Date:  2019-08-27

Review 7.  Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.

Authors:  Romeo Gabriel Mihaila
Journal:  Oncol Lett       Date:  2021-07-03       Impact factor: 2.967

8.  Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.

Authors:  Naohiro Sekiguchi; Shinya Rai; Wataru Munakata; Kenshi Suzuki; Hiroshi Handa; Hirohiko Shibayama; Tomoyuki Endo; Yasuhito Terui; Noriko Iwaki; Noriko Fukuhara; Hiro Tatetsu; Shinsuke Iida; Takayuki Ishikawa; Daisuke Iguchi; Koji Izutsu
Journal:  Cancer Sci       Date:  2022-04-06       Impact factor: 6.518

Review 9.  Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic.

Authors:  Dipti Talaulikar; Ranjana H Advani; Andrew R Branagan; Christian Buske; Meletios A Dimopoulos; Shirley D'Sa; Maria J Kersten; Veronique Leblond; Monique C Minnema; Roger G Owen; Maria Lia Palomba; Alessandra Tedeschi; Judith Trotman; Marzia Varettoni; Josephine M Vos; Steven P Treon; Efstathios Kastritis; Jorge J Castillo
Journal:  Hemasphere       Date:  2020-07-30

Review 10.  The Care of the Leukemic Patients in Times of SARS-CoV-2.

Authors:  Nabin Raj Karki; Thuy Le; Jorge Cortes
Journal:  Curr Oncol Rep       Date:  2021-08-03       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.